Responses
Clinical and epidemiological research
Extended report
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
Compose a Response to This Article
Other responses
No responses have been published for this article.